GlassScriptPhysician profile
Pinky Kotwal
NPI 1083645444
$3,075.49
in general payments reported to CMS, 2019-2025
38 companies · $728 in 2025
The $728 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $571 · 2020: $85.69 · 2021: $259 · 2022: $527 · 2023: $357 · 2024: $547 · 2025: $728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,632.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $536.78 | 2021-2025 | |
| Amgen INC. | $368.05 | 2019-2025 | Evenity, Prolia, Prolia |
| Pharming Healthcare, INC. | $183.92 | 2019 | |
| Lilly USA, LLC | $172.63 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $167.59 | 2020-2025 | |
| Abbott Laboratories | $166.40 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $137.84 | 2021-2025 | Ozempic, Rybelsus |
| Phathom Pharmaceuticals, INC. | $133.27 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $109.63 | 2019-2025 | Tezspire, Airsupra |
| Strongbridge US INC. | $106.85 | 2019-2020 | |
| Grifols USA, LLC | $101.15 | 2024-2025 | Prolastin-C Liquid |
| Corcept Therapeutics | $95.79 | 2024-2025 | Korlym |
| Glaxosmithkline, LLC. | $72.51 | 2019-2024 | Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $68.61 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $66.94 | 2019 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pinky Kotwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.